---
schema_version: "secwatch.filing_event.v1"
accession: "0001048477-25-000101"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2025-10-07T23:59:59+00:00"
generated_at: "2026-05-17T04:23:32.179922+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "medium"
source: SEC EDGAR
---

# BioMarin expects $221M IPR&D charge from Inozyme acquisition, ~$1.10 EPS hit in Q3 2025

## Summary
- Acquired IPR&D charge of ~$221M pre-tax from July 1 Inozyme Pharma acquisition.
- Charge reduces both GAAP and Non-GAAP diluted EPS by approximately $1.10 for Q3 2025.
- Q3 2025 results not finalized; actual results may differ from preliminary estimates.
- BioMarin does not forecast IPR&D charges due to uncertainty of timing and magnitude.

## SEC filing metadata
- accession: 0001048477-25-000101
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2025-10-07T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: medium
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000104847725000101/0001048477-25-000101-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000104847725000101/bmrn-20251007.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001048477-25-000101
- JSON: https://secwatch.observer/filing/0001048477-25-000101.json
- Plain text: https://secwatch.observer/filing/0001048477-25-000101.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.